Pages that link to "Q36499146"
The following pages link to Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition (Q36499146):
Displaying 50 items.
- tumor protein p53 (Q283350) (← links)
- MDM2 proto-oncogene (Q2639180) (← links)
- Ribosomal protein S27-like and S27 interplay with p53-MDM2 axis as a target, a substrate and a regulator (Q24318162) (← links)
- Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development (Q24628811) (← links)
- Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy (Q24651380) (← links)
- Chemical Variations on the p53 Reactivation Theme (Q26749008) (← links)
- Drugging the undruggables: exploring the ubiquitin system for drug development (Q26752823) (← links)
- Targeting the ubiquitin pathway for cancer treatment (Q26866185) (← links)
- Features of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinity (Q26996645) (← links)
- Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents (Q27318801) (← links)
- Crystal Structures of Human MdmX (HdmX) in Complex with p53 Peptide Analogues Reveal Surprising Conformational Changes (Q27653453) (← links)
- Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX (Q27653993) (← links)
- Apamin as a novel template for structure-based rational design of potent peptide activators of p53 (Q27657769) (← links)
- Structure-based Design of High Affinity Peptides Inhibiting the Interaction of p53 with MDM2 and MDMX (Q27658148) (← links)
- Systematic Mutational Analysis of Peptide Inhibition of the p53–MDM2/MDMX Interactions (Q27660219) (← links)
- Limitations of Peptide Retro-inverso Isomerization in Molecular Mimicry (Q27660480) (← links)
- A Left-Handed Solution to Peptide Inhibition of the p53-MDM2 Interaction (Q27661400) (← links)
- D-peptide inhibitors of the p53–MDM2 interaction for targeted molecular therapy of malignant neoplasms (Q27663612) (← links)
- Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization (Q27670558) (← links)
- An Ultrahigh Affinity d -Peptide Antagonist Of MDM2 (Q27681154) (← links)
- Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness (Q28077156) (← links)
- The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design (Q28289090) (← links)
- mRNA Display Selection of an Optimized MDM2-Binding Peptide That Potently Inhibits MDM2-p53 Interaction (Q28386936) (← links)
- A spiroligomer α-helix mimic that binds HDM2, penetrates human cells and stabilizes HDM2 in cell culture (Q28484490) (← links)
- Structure and activity analysis of Inauhzin analogs as novel antitumor compounds that induce p53 and inhibit cell growth (Q28484540) (← links)
- The pharmacodynamics of the p53-Mdm2 targeting drug Nutlin: the role of gene-switching noise (Q28542661) (← links)
- Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737 (Q28542684) (← links)
- Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment (Q28548249) (← links)
- Modes of p53 regulation (Q29615657) (← links)
- Therapeutic considerations for Mdm2: not just a one trick pony (Q30380490) (← links)
- Pharmacological reactivation of mutant p53: from protein structure to the cancer patient (Q30389604) (← links)
- P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis. (Q33430602) (← links)
- N-acylpolyamine inhibitors of HDM2 and HDMX binding to p53. (Q33514226) (← links)
- Identification and characterization of the first small molecule inhibitor of MDMX (Q33524716) (← links)
- p53-mediated heterochromatin reorganization regulates its cell fate decisions (Q33565827) (← links)
- Aberrant activation of p53 due to loss of MDM2 or MDMX causes early lens dysmorphogenesis (Q33570731) (← links)
- New targets for the treatment of follicular lymphoma (Q33587396) (← links)
- A covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination (Q33626131) (← links)
- Functional profiling of p53-binding sites in Hdm2 and Hdmx using a genetic selection system (Q33635059) (← links)
- Targeting p53 for Novel Anticancer Therapy (Q33655329) (← links)
- Targeting tumor suppressor networks for cancer therapeutics (Q33657519) (← links)
- Inhibitors of ubiquitin E3 ligase as potential new antimalarial drug leads (Q33759673) (← links)
- Mdm2 links genotoxic stress and metabolism to p53 (Q33788018) (← links)
- A cell-based high-throughput assay for the screening of small-molecule inhibitors of p53-MDM2 interaction (Q33864504) (← links)
- MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function (Q33930068) (← links)
- Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia (Q33997232) (← links)
- The p53 orchestra: Mdm2 and Mdmx set the tone (Q34020353) (← links)
- Autoactivation of the MDM2 E3 ligase by intramolecular interaction (Q34056449) (← links)
- Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism (Q34079481) (← links)
- Beta-peptides with improved affinity for hDM2 and hDMX. (Q34080613) (← links)